BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Clinical trial NCT06205706 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06205706
Sponsor: BioInvent International AB
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumors Non Small Cell Lung Cancer Hepatocellular Carcinoma

Start date: 2023-12-04
Primary completion: 2027-07-14
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.